Cytodyn (Leronlimab) is a Legendary Biotech that W
Post# of 155304
(Total Views: 639)
Posted On: 06/20/2023 9:01:24 AM
Cytodyn (Leronlimab) is a Legendary Biotech that Will Rise Again
By
Boe Rimes
June 20, 2023
Cytodyn, Inc., (OTCQB: CYDY) – is easily one of the most exciting stocks in small caps that is baselined at $0.25 support levels with little downside and serious upside potential. Driven down into oblivion by an aggressive short position, ongoing investigations and a clinical hold on its HIV program in the United States, CYDY trades at a fraction of its former value and is under accumulation by an enormous shareholder base. Investors are looking for Cytodyn to advance the development of the NASH phase 2b clinical trial for submission to the FDA and for the clinical hold to be lifted so that Cytodyn can partner with a major in the pharma space to advance its flagship Leronlmab through HIV trials and eventual FDA approval as already laid out in the investor presentation on December 7th of last year. Considering Cytodyn’s current market valuation and the potential value of Leronlimab, the Company is also a buyout candidate here by any one of the big pharma players.
Leronlimab is a monoclonal lab-made antibody targeting the CCR5 receptor found on T lymphocytes of the human immune system which plays a role in numerous disease processes such as HIV, cancer and numerous other indications. In HIV, Leronlimab prevents HIV from using the CCR5 receptor as an entry gateway for healthy cells and interferes with the virus’s ability to enter healthy cells, stopping viral replication. It also prevents the virus-cell binding at a distinct site in the CCR5 co-receptor without interfering with its natural activity. Since early testing of Leronlimab began the drug has demonstrated “potent, rapid, prolonged, highly significant antiviral activity and could become the standard of care for multiple billion-dollar markets including HIV, Nash, and solid-tumors, and autoimmune Diseases. We will be updating on CYDY when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
https://newsytrends.com/2023/06/20/cytodyn-le...ise-again/
By
Boe Rimes
June 20, 2023
Cytodyn, Inc., (OTCQB: CYDY) – is easily one of the most exciting stocks in small caps that is baselined at $0.25 support levels with little downside and serious upside potential. Driven down into oblivion by an aggressive short position, ongoing investigations and a clinical hold on its HIV program in the United States, CYDY trades at a fraction of its former value and is under accumulation by an enormous shareholder base. Investors are looking for Cytodyn to advance the development of the NASH phase 2b clinical trial for submission to the FDA and for the clinical hold to be lifted so that Cytodyn can partner with a major in the pharma space to advance its flagship Leronlmab through HIV trials and eventual FDA approval as already laid out in the investor presentation on December 7th of last year. Considering Cytodyn’s current market valuation and the potential value of Leronlimab, the Company is also a buyout candidate here by any one of the big pharma players.
Leronlimab is a monoclonal lab-made antibody targeting the CCR5 receptor found on T lymphocytes of the human immune system which plays a role in numerous disease processes such as HIV, cancer and numerous other indications. In HIV, Leronlimab prevents HIV from using the CCR5 receptor as an entry gateway for healthy cells and interferes with the virus’s ability to enter healthy cells, stopping viral replication. It also prevents the virus-cell binding at a distinct site in the CCR5 co-receptor without interfering with its natural activity. Since early testing of Leronlimab began the drug has demonstrated “potent, rapid, prolonged, highly significant antiviral activity and could become the standard of care for multiple billion-dollar markets including HIV, Nash, and solid-tumors, and autoimmune Diseases. We will be updating on CYDY when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.
https://newsytrends.com/2023/06/20/cytodyn-le...ise-again/
(4)
(0)